Patrick Toomey said...

It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.

Toomey argues that Sarbanes-Oxley data is irrelevant for pre-revenue biotech firms.

07/19/2011

More Patrick Toomey Quotes

I just think that fare evasion is an important violation of the law that the FTA should be tracking.

Mike has a record of public service.

A quasi-regulatory body like NASDAQ should not be creating and enforcing social policy in America.

last year's infrastructure law seems to have been driven more by Democratic political imperatives.